Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Abstract Background Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain. Aim and methods We therefore evaluate the effects of a...

Full description

Bibliographic Details
Main Authors: Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda, Koichi Node
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Anagliptin
Sitagliptin
Lipid metabolisms
Lathosterol
Online Access:http://link.springer.com/article/10.1186/s12933-019-0965-3

Internet

http://link.springer.com/article/10.1186/s12933-019-0965-3

Similar Items